12:00 AM
 | 
Feb 22, 2000
 |  BC Week In Review  |  Company News  |  Deals

Aquila, Elan, Progenics deal

AQLA received milestone payments from partners PGNX, which uses AQLA’s Stimulon adjuvant QS-21 in its cancer program,...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >